Virtu Financial LLC Purchases New Shares in ImmunityBio, Inc. (NASDAQ:IBRX)

Virtu Financial LLC acquired a new position in ImmunityBio, Inc. (NASDAQ:IBRX) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 13,608 shares of the company’s stock, valued at approximately $51,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Bank of New York Mellon Corp raised its holdings in shares of ImmunityBio by 37.9% in the second quarter. Bank of New York Mellon Corp now owns 621,536 shares of the company’s stock valued at $3,928,000 after buying an additional 170,742 shares during the last quarter. CIBC Asset Management Inc bought a new position in shares of ImmunityBio in the second quarter worth about $118,000. Rhumbline Advisers lifted its position in shares of ImmunityBio by 13.3% during the second quarter. Rhumbline Advisers now owns 211,677 shares of the company’s stock worth $1,338,000 after purchasing an additional 24,802 shares in the last quarter. Wealth Effects LLC grew its stake in shares of ImmunityBio by 33.6% during the second quarter. Wealth Effects LLC now owns 87,500 shares of the company’s stock valued at $553,000 after purchasing an additional 22,000 shares during the last quarter. Finally, Victory Capital Management Inc. increased its holdings in shares of ImmunityBio by 16.0% in the second quarter. Victory Capital Management Inc. now owns 19,953 shares of the company’s stock valued at $126,000 after purchasing an additional 2,746 shares in the last quarter. Institutional investors and hedge funds own 8.58% of the company’s stock.

Analyst Ratings Changes

IBRX has been the topic of a number of recent research reports. D. Boral Capital reiterated a “buy” rating and issued a $30.00 price objective on shares of ImmunityBio in a research report on Friday. EF Hutton Acquisition Co. I upgraded ImmunityBio to a “strong-buy” rating in a report on Wednesday, October 23rd.

ImmunityBio Price Performance

Shares of NASDAQ IBRX opened at $2.62 on Friday. ImmunityBio, Inc. has a fifty-two week low of $2.61 and a fifty-two week high of $10.53. The firm has a market capitalization of $1.83 billion, a P/E ratio of -2.85 and a beta of 0.86. The company’s 50 day simple moving average is $4.49 and its 200 day simple moving average is $4.74.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.